Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance

References

• Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283:1121–1125.
   PubMed Web of Science ®Google Scholar
• Bergsagel DE, Bailey AJ, Langley GR, et al. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979;301:743–748.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Erskine S, Edelman D, et al. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the medical research council's working party on leukemia in adults. Br J Cancer. 1987;55:523–529.
   PubMed Web of Science ®Google Scholar
• Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med. 1986;105:360–367.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Haessler J, et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. Blood. 2008;111:94–100.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Buadi F, McClune B, et al. Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Bone Marrow Transplant. 2007;40:759–764.
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol. 1996;95:349–353.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759–1769.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–1781.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–1791.
   PubMed Web of Science ®Google Scholar
• Chen T, Fallah M, Brenner H, et al. Risk of second primary cancers in multiple myeloma survivors in German and Swedish cancer registries. Sci Rep. 2016;6:22084.
   PubMed Web of Science ®Google Scholar
• Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer. 2001;85:997–1005.
   PubMed Web of Science ®Google Scholar
• Razavi P, Rand KA, Cozen W, et al. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J. 2013;3:e121.
   PubMed Web of Science ®Google Scholar
• Storm HH, Prener A. Second cancer following lymphatic and hematopoietic cancers in Denmark, 1943-80. Natl Cancer Inst Monogr. 1985;68:389–409.
   PubMedGoogle Scholar
• Tzeng HE, Lin CL, Tsai CH, et al. Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study. PLoS One. 2013;8:e68041.
   Google Scholar
• Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011;118:4086–4092.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Flanders WD, Pellett PE. Occurrence of primary cancers in association with multiple myeloma and Kaposi's sarcoma in the United States, 1973-1995. Int J Cancer. 2000;85:453–456.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Hauke RJ, Bonthu N, et al. Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma–a SEER based study. Anticancer Res. 2012;32:4507–4515.
   PubMed Web of Science ®Google Scholar
• Li XL, Xu JH. MTHFR polymorphism and the risk of prostate cancer: a meta-analysis of case-control studies. Prostate Cancer Prostatic Dis. 2012;15:244–249.
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Giannouli S, Rodopoulou P, et al. The role of MTHFR gene in multiple myeloma. J Hum Genet. 2008;53:499–507.
   PubMed Web of Science ®Google Scholar
• Ailawadhi S, Swaika A, Razavi P, et al. Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups. Blood Cancer J. 2014;4:e243.
   Google Scholar
• Jonsdottir G, Lund SH, Bjorkholm M, et al. Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. Haematologica. 2016;101:e145–e148.
   Google Scholar
• Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333–342.
   PubMed Web of Science ®Google Scholar
• Rifkin RM, Abonour R, Shah JJ, et al. Connect MM(R) - the multiple myeloma disease registry: incidence of second primary malignancies in patients treated with lenalidomide. Leuk Lymphoma. 2016;57:2228–2231.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31:448–455.
   PubMed Web of Science ®Google Scholar
• Miguel JFS, Richardson PG, Orlowski RZ, et al. Risk of second primary malignancies (SPMs) following bortezomib (Btz)-based therapy: analysis of four phase 3 randomized controlled trials in previously untreated or relapsed multiple myeloma (MM). Blood. 2011;118:2933–2933.
   Web of Science ®Google Scholar
• Engelhardt M, Ihorst G, Landgren O, et al. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. Haematologica. 2015;100:1340–1349.
   PubMed Web of Science ®Google Scholar
• Hanzis C, Ojha RP, Hunter Z, et al. Associated malignancies in patients with Waldenstrom's macroglobulinemia and their kin. Clin Lymphoma Myeloma Leuk. 2011;11:88–92.
   PubMed Web of Science ®Google Scholar
• Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27:250–255.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Tedeschi A, Arcaini L, et al. Risk of second cancers in Waldenstrom macroglobulinemia. Ann Oncol. 2012;23:411–415.
   PubMed Web of Science ®Google Scholar
• Morra E, Varettoni M, Tedeschi A, et al. Associated cancers in Waldenstrom macroglobulinemia: clues for common genetic predisposition. Clin Lymphoma Myeloma Leuk. 2013;13:700–703.
   PubMed Web of Science ®Google Scholar
• Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31:301–307.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Hunter ZR, et al. Incidence of secondary malignancies among patients with Waldenstrom macroglobulinemia: an analysis of the SEER database. Cancer. 2015;121:2230–2236.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Kanan S, et al. Survival outcomes of secondary cancers in patients with Waldenstrom macroglobulinemia: an analysis of the SEER database. Am J Hematol. 2015;90:696–701.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–569.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102:3759–3764.
   PubMed Web of Science ®Google Scholar
• Roeker LE, Larson DR, Kyle RA, et al. Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients. Leukemia. 2013;27:1391–1393.
   PubMed Web of Science ®Google Scholar
• Turesson I, Kovalchik SA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123:338–345.
   PubMed Web of Science ®Google Scholar
• Korde N, Liu QY, Kwok M, et al. Early myelodysplastic changes present in substantial proportion of monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) patients. Blood. 2012;120:1805–1805.
   Web of Science ®Google Scholar